Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
Add more filters










Database
Language
Publication year range
1.
J Thorac Cardiovasc Surg ; 112(4): 1081-9, 1996 Oct.
Article in English | MEDLINE | ID: mdl-8873736

ABSTRACT

BACKGROUND: Patients having cardiac operations often require blood transfusions. Aprotinin reduces the need for blood transfusions during coronary artery bypass graft operations. To determine the safety and effectiveness of aprotinin in reducing the use of allogeneic blood and postoperative mediastinal chest tube drainage, we studied 212 patients undergoing primary sternotomy for valve replacement or repair. METHODS: This study was multicenter, randomized, prospective, double-blind, and placebo-controlled. Patients received high-dose aprotinin (n = 71), low-dose aprotinin (n = 70), or placebo (n = 71). The study medication was given as a loading dose followed by a continuous infusion and pump prime dose. Heparin administration was standardized. Transfusions, postoperative mediastinal shed blood, and adverse events were tracked. RESULTS: Demographic profiles were similar among the treatment groups. Aprotinin did not decrease the percentage of patients receiving transfusions when compared with placebo (high-dose aprotinin, 63%, p = 0.092; low-dose aprotinin, 52%, p = 0.592; placebo, 48%). Aprotinin was associated with a reduction in the volume of mediastinal shed blood (high-dose aprotinin vs placebo, p = 0.002; low-dose aprotinin vs placebo, p = 0.017). Adverse events were equally distributed among the treatment groups except for postoperative renal dysfunction (high-dose aprotinin, 11%; low-dose aprotinin, 7%; placebo, 0%; p = 0.01). A disproportionate number of patients in the high-dose aprotinin group with postoperative renal dysfunction also had diabetes mellitus. CONCLUSIONS: Aprotinin treatment in this population did not reduce allogeneic blood use, although there were significant reductions in the volume of mediastinal shed blood.


Subject(s)
Aprotinin/administration & dosage , Heart Valves/surgery , Hemostatics/administration & dosage , Aprotinin/adverse effects , Blood Loss, Surgical , Blood Transfusion , Chest Tubes , Double-Blind Method , Drainage , Erythrocyte Volume , Female , Hemoglobins/analysis , Hemostatics/adverse effects , Humans , Kidney/drug effects , Male , Middle Aged , Prospective Studies
2.
Ann Thorac Surg ; 59(1): 132-6, 1995 Jan.
Article in English | MEDLINE | ID: mdl-7529484

ABSTRACT

Two hundred sixteen patients undergoing coronary artery bypass graft procedures were randomized to receive either high-dose aprotinin or placebo. Clinically important postoperative renal insufficiency was infrequent, with a single patient (0.9%) from each group requiring dialysis. Although increases in the serum creatinine level occurred postoperatively in more patients who received aprotinin (20/108) than in those given placebo (13/108), the difference between the two groups was not statistically significant (p = 0.186), and the increases were generally small and transient. Likewise, there was no difference between the groups in terms of the incidence of abnormal serum electrolyte levels, blood urea nitrogen levels, or urinalysis findings, or in the frequency of abnormal creatinine clearance rates. Under the conditions described, aprotinin use does not appear to be associated with a significant risk of serious renal toxicity.


Subject(s)
Aprotinin/pharmacology , Coronary Artery Bypass , Kidney/drug effects , Postoperative Complications , Blood Urea Nitrogen , Creatinine/blood , Double-Blind Method , Electrolytes/blood , Female , Humans , Kidney/physiopathology , Male , Middle Aged , Renal Insufficiency/etiology , Urine
3.
J Thorac Cardiovasc Surg ; 107(2): 543-51; discussion 551-3, 1994 Feb.
Article in English | MEDLINE | ID: mdl-7508070

ABSTRACT

The purpose of this study was to evaluate the efficacy and safety of aprotinin in a U.S. population of patients undergoing coronary artery bypass grafting. Early vein graft patency rates were assessed by ultrafast computed tomography. A total of 216 patients at five centers were randomized to receive either high-dose aprotinin or placebo during the operation; 151 patients underwent primary operation, and 65 underwent repeat procedures. Total blood product exposures in the primary group were 2.2 per patient receiving aprotinin as compared with 5.7 per patient receiving placebo (p = 0.010). The repeat group had 0.3 exposures per patient receiving aprotinin as compared with 10.7 per patient receiving placebo (p = < 0.001). Consistent reductions in the percent of patients requiring donor red blood cells and in the number of units of platelets, fresh frozen plasma, and cryoprecipitate required were associated with the use of aprotinin in both primary and repeat groups. Mortality was 5.6% in the aprotinin group and 3.7% in the placebo group (p = 0.517). In the primary group, clinical diagnoses of myocardial infarction were made in 8.9% of patients receiving aprotinin as compared with 5.6% of the patients receiving placebo (p = 0.435). In the repeat group, infarctions occurred in 10.3% of patients receiving aprotinin and 8.3% of patients receiving placebo (p = 1.000). Secondary analysis of electrocardiograms and available enzyme data showed no significant difference in infarction rates between the treatment groups. There was no difference in clinically significant renal dysfunction. The early vein graft patency rates were 92.0% in the aprotinin group and 95.1% in the placebo group (p = 0.248). In this study, aprotinin was effective in reducing bleeding and blood product transfusion rates, and its use was not associated with an increase in complications. An adverse effect on early vein graft patency rates was not demonstrated, but the number of grafts assessed was insufficient for absolute conclusions in this regard.


Subject(s)
Aprotinin/therapeutic use , Blood Loss, Surgical/prevention & control , Coronary Artery Bypass , Hemostasis, Surgical/methods , Aprotinin/adverse effects , Blood Transfusion , Blood Volume , Coronary Artery Bypass/mortality , Double-Blind Method , Graft Occlusion, Vascular/chemically induced , Graft Occlusion, Vascular/diagnostic imaging , Humans , Myocardial Infarction/etiology , Postoperative Complications , Reoperation , Tomography, X-Ray Computed
4.
Clin Pharmacol Ther ; 40(4): 373-7, 1986 Oct.
Article in English | MEDLINE | ID: mdl-3530585

ABSTRACT

The incidence of potentially serious drug-related elevations of BUN or serum creatinine was examined among 1468 patients with rheumatoid arthritis or osteoarthritis who took daily therapeutic doses of aspirin, ibuprofen, or oxaprozin, an investigational nonsteroidal antiinflammatory drug (NSAID), in multicenter clinical trials. Algorithms were developed to identify patients with potentially important elevations of these renal laboratory parameters and to assess the possible relation between these elevations and the study drugs. All three drugs were associated with a low (4% to 6%) incidence of potentially significant elevations in renal function parameters. Changes considered serious occurred in only three (less than 1%) patients (one treated with oxaprozin and two with ibuprofen), all of whom were receiving concomitant diuretic therapy. None of the changes led to adverse clinical consequences. Thus despite recent controversy regarding the renal safety of NSAIDs, all three drugs proved safe in these studies, despite the fact that aspirin and ibuprofen were given in doses equal to or higher than those used for over-the-counter indications.


Subject(s)
Arthritis, Rheumatoid/drug therapy , Aspirin/therapeutic use , Ibuprofen/therapeutic use , Kidney/drug effects , Osteoarthritis/drug therapy , Adult , Aged , Aspirin/adverse effects , Blood Urea Nitrogen , Clinical Trials as Topic , Creatinine/metabolism , Double-Blind Method , Humans , Ibuprofen/adverse effects , Middle Aged , Oxaprozin , Propionates/therapeutic use
SELECTION OF CITATIONS
SEARCH DETAIL
...